# The Lancet Haematology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/the-lancet-haematology/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 2352-3026 |
| ISSNs | 2352-3026,2451-9960 |
| OpenAlex ID | https://openalex.org/S2531671668 |
| Publisher | Elsevier BV |

## Journal papers

Showing 12 of 29.

- [Coagulation abnormalities and thrombosis in patients with COVID-19](https://scholariq.org/papers/coagulation-abnormalities-and-thrombosis-in-patients-with-covid-19/)
- [Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021](https://scholariq.org/papers/global-regional-and-national-prevalence-and-mortality-burden-of-sickle-cell/)
- [Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021](https://scholariq.org/papers/prevalence-years-lived-with-disability-and-trends-in-anaemia-burden-by-severity/)
- [Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study](https://scholariq.org/papers/derivation-and-external-validation-of-the-plasmic-score-for-rapid-assessment-of/)
- [Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial](https://scholariq.org/papers/post-thrombotic-syndrome-after-catheter-directed-thrombolysis-for-deep-vein/)
- [Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials](https://scholariq.org/papers/iron-absorption-from-oral-iron-supplements-given-on-consecutive-versus-alternate/)
- [Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial](https://scholariq.org/papers/rivaroxaban-compared-with-standard-anticoagulants-for-the-treatment-of-acute/)
- [Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial](https://scholariq.org/papers/discontinuation-of-dasatinib-in-patients-with-chronic-myeloid-leukaemia-who-have/)
- [Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis](https://scholariq.org/papers/association-of-busulfan-exposure-with-survival-and-toxicity-after-haemopoietic/)
- [Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis](https://scholariq.org/papers/association-between-anti-thymocyte-globulin-exposure-and-cd4-immune/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies](https://scholariq.org/papers/prognostic-value-of-pet-ct-after-first-line-therapy-in-patients-with-follicular/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.